New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
05:17 EDTADXS, MRKAdvaxis, Merck enter clinical trial collaboration agreement
Advaxis (ADXS) has entered into a clinical trial collaboration agreement with Merck (MRK), through its subsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's investigational anti PD-1 antibody, pembrolizumab. The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer. Both ADXS-PSA and pembrolizumab are investigational members of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer. Preclinical evidence suggests that Advaxis Lm-LLO immunotherapies in combination with a PD-1 inhibitor may lead to an enhanced anti-tumor immune response.
News For ADXS;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
07:20 EDTMRKMerck selloff overdone, says SunTrust
After meeting with four senior Merck executives, SunTrust says that the selloff in the stock over concerns about the company's Januvia franchise are overdone. The firm expects the company's diabetes drugs to generate over $8.5B in revenue in 2020, up from less than $6B currently, through the launch of several new treatments within the next two years. It is upbeat on the outlook for the company's Keytruda cancer treatment and reiterates a $72 price target and Buy rating.
September 2, 2015
08:04 EDTMRKMerck says FDA approves pediatric indication for Emend capsules
Subscribe for More Information
September 1, 2015
09:04 EDTMRKMerck reports new analyses from IMPROVE-IT study with Vytorin
Subscribe for More Information
August 30, 2015
12:33 EDTMRKDividend-rich blue chips look attractive amid market volatility, Barron's says
Subscribe for More Information
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
08:05 EDTADXSAdvaxis enters licensing agreement with Knight Therapeutics
Advaxis announced that the company has entered into a licensing agreement with Knight Therapeutics to commercialize in Canada Advaxis's product portfolio including its three lead drug candidates: axalimogene filolisbac for human papilloma virus, or HPV,-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In connection with the licensing agreement, Knight is purchasing directly from Advaxis 359,454 shares at $13.91 per share, which represents a 7% premium to the price of Advaxis's common stock at market close on August 25. In addition, Sectoral Asset Management, a leading Canadian-based global healthcare investment advisor, is purchasing 1.44M shares at $13.91 per share directly from Advaxis on behalf of its clients. The combined gross proceeds to Advaxis from these direct investments is $25M.
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use